Combined pyrotinib and fulvestrant for hormone receptor-positive and HER2-positive metastatic breast cancer: A multicenter, single-arm, phase II trial.
Zhao J, Yu Y, Ren W, Ding L, Chen Y, Yuan P, Yue J, Yang Y, Zou G, Chen T, Chai J, Zhang L, Wu W, Zeng Y, Gui X, Cai Y, Luo S, Yuan Z, Zhang K, Yao H, Wang Y.
Zhao J, et al. Among authors: zou g.
MedComm (2020). 2024 Dec 20;6(1):e70031. doi: 10.1002/mco2.70031. eCollection 2025 Jan.
MedComm (2020). 2024.
PMID: 39712455
Free PMC article.